Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation

Cytomegalovirus infection and its reactivation is frequent after solid organs and hematopoietic stem cell transplantation, and this infection can cause significant impact on transplantation outcomes. In mouse experimental models and in hematopoietic stem cells, an infusion in the presence of strain-specific anti-cytomegolovirus, was protective. There is the need for antibodies specific for the strain that was presented. Commercial immunoglobulin infusions were tried in bone marrow transplantation and solid organ transplantation as prophylactic or therapeutic measures against cytomegalovirus, but trials did not show efficacy, probably because there were not enough antibodies against the specific infecting strain.

Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voight V, et al. Strain-specific antibody theraphy prevents cytomegalovirus reactivation after transplantation. Science. 2019;363(6424):288-93. https://doi.org/10.1126/science.aat0066.

 

Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation

Comments